Emergent BioSolutions executive reports stock holdings
Emergent BioSolutions Inc. reported the initial equity holdings of executive vice president and chief growth officer Stephanie Duatschek.
Rhea-AI Filing Summary
Emergent BioSolutions Inc. reported the initial equity holdings of executive vice president and chief growth officer Stephanie Duatschek. She holds 197,416 shares of common stock, consisting of 55,639 shares and 141,777 unvested RSUs that generally vest in three equal annual installments. She also holds several employee stock options on common stock, with exercise prices ranging from $2.33 to $59.07 per share and expiration dates between 2028 and 2033. For options granted in 2021–2025, all or a portion of the underlying shares are already vested and exercisable as described in the footnotes.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Duatschek Stephanie
Role
EVP, CGO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (Right to buy) F2 | -- | -- | -- |
| holding | Employee Stock Option (Right to buy) (Common Stock) F3 | -- | -- | -- |
| holding | Employee Stock Option (Right to buy) (Common Stock) F4 | -- | -- | -- |
| holding | Employee Stock Option (Right to buy) (Common Stock) F5 | -- | -- | -- |
| holding | Employee Stock Option (Right to buy) (Common Stock) F6 | -- | -- | -- |
| holding | Employee Stock Option (Right to buy) (Common Stock) F7 | -- | -- | -- |
| holding | Employee Stock Option (Right to buy) (Common Stock) F8 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (Right to buy) — 6,772 contracts (Direct);
Employee Stock Option (Right to buy) (Common Stock) — 251,123 contracts (Direct);
Common Stock — 197,416 shares (Direct)
Footnotes (8)
- F1. Consists of 55,639 shares of common stock and 141,777 unvested RSUs from the Emergent Stock Incentive Plan. Each RSU represents a right to receive one share of common stock. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant.
- F2. Granted on July 9, 2021 and as of the date of this filing all of the shares underlying the option are vested and exercisable.
- F3. Granted on March 1, 2022 and as of the date of this filing all of the shares underlying the option are vested and exercisable.
- F4. Granted on March 6, 2023 and as of the date of this filing all of the shares underlying the option are vested and exercisable.
- F5. Granted on June 9, 2023 and as of the date of this filing all of the shares underlying the option are vested and exercisable.
- F6. Granted on March 13, 2024 and vests in three installments beginning on the day prior to the anniversary date of the grant. As of the date of this filing, 83,250 of the shares underlying the option are vested and exercisable.
- F7. Granted on March 6, 2025 and vests in three installments beginning on the day prior to the anniversary date of the grant. As of the date of this filing, 20,813 of the shares underlying the option are vested and exercisable.
- F8. Granted on March 3, 2026 and vests in three installments beginning on the day prior to the anniversary date of the grant.
Key Figures
Total common stock beneficially owned: 197,416 shares
Direct common shares: 55,639 shares
Unvested RSUs: 141,777 RSUs
+4 more
7 metrics
Total common stock beneficially owned
197,416 shares
Direct and RSU-based holdings reported for Stephanie Duatschek
Direct common shares
55,639 shares
Portion of total holdings classified as common stock
Unvested RSUs
141,777 RSUs
Rights to receive common stock under Emergent Stock Incentive Plan
Option exercise price (2021 grant)
$59.07 per share
Employee stock option expiring July 8, 2028 on 6,772 underlying shares
Largest option grant
125,000 shares at $2.33
Employee stock option expiring March 12, 2031, partially vested
Option grant 2025
62,500 shares at $5.80
Employee stock option expiring March 5, 2032, partially vested
Recent option grant 2026
44,834 shares at $8.99
Employee stock option expiring March 2, 2033, three-installment vesting
Key Terms
Restricted Stock Unit, Emergent Stock Incentive Plan, Employee Stock Option (Right to buy), vested and exercisable
4 terms
Restricted Stock Unit financial
"Consists of 55,639 shares of common stock and 141,777 unvested RSUs..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Emergent Stock Incentive Plan financial
"...141,777 unvested RSUs from the Emergent Stock Incentive Plan."
Employee Stock Option (Right to buy) financial
"Employee Stock Option (Right to buy) (Common Stock)..."
vested and exercisable financial
"all of the shares underlying the option are vested and exercisable."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Emergent BioSolutions (EBS) report about Stephanie Duatschek’s stock ownership?
The filing reports that Stephanie Duatschek, EVP and CGO of Emergent BioSolutions, beneficially owns 197,416 shares of common stock, including both directly held shares and unvested RSUs, plus multiple employee stock option grants on common stock.
What stock options on EBS common stock does Stephanie Duatschek have?
She holds several employee stock options on EBS common stock with exercise prices from $2.33 to $59.07 per share and expiration dates between 2028 and 2033, covering underlying share amounts from 2,308 to 125,000 shares.
What is the largest single EBS option grant held by Stephanie Duatschek?
Her largest grant is an employee stock option with an exercise price of $2.33 per share, expiring March 12, 2031, covering 125,000 underlying shares of Emergent BioSolutions common stock, a portion of which is already vested and exercisable.
How are Stephanie Duatschek’s more recent EBS option grants structured to vest?
Options granted on March 13, 2024, March 6, 2025, and March 3, 2026 vest in three installments, beginning on the day prior to each grant’s anniversary; substantial portions of the 2024 and 2025 grants are already vested and exercisable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
